Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.30 |
| ▸ | PPARA | Q07869 | 1/20 | 0.30 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.30 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7871683 | 0.86 | EPHX1 (0.40) | EPHX1NPY5RIDO1CNR1CNR2 | |
| SCHEMBL7870267 | 0.83 | NPY5R (0.39) | EPHX1NPY5RIDO1CNR1CNR2 | |
| SCHEMBL7863546 | 0.80 | NPY5R (0.39) | EPHX1NPY5RIDO1CNR1CNR2 | |
| SCHEMBL7872382 | 0.79 | NPY5R (0.40) | EPHX1NPY5RIDO1CNR1CNR2 | |
| SCHEMBL7863412 | 0.78 | NPY5R (0.36) | EPHX1NPY5RIDO1CNR1CNR2 | |
| SCHEMBL7871566 | 0.77 | CA14 (0.35) | IDO1CNR1CNR2 | |
| SCHEMBL7868751 | 0.76 | CA14 (0.35) | EPHX1NPY5R | |
| SCHEMBL8908698 | 0.72 | EPHX1 (0.32) | EPHX1NPY5RIDO1CNR1CNR2 | |
| SCHEMBL7863518 | 0.67 | EPHX1 (0.36) | EPHX1NPY5RIDO1CNR1CNR2 | |
| Hydrochloric Acid SCHEMBL7871619 | 0.66 | EPHX1 (0.36) | EPHX1NPY5RIDO1CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010051631-A1 | Tricyclic compounds, their production and use | TAKATANI MUNEO (JP) | 2001-12-13 | — | — | US | disclosed |
| US-6251905-B1 | Tricyclic compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-06-26 | — | — | US | disclosed |
| EP-0771319-A1 | TRICYCLIC COMPOUNDS, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1997-05-07 | — | — | EP | disclosed |
| WO-1996002542-A1 | TRICYCLIC COMPOUNDS, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010051631-A1 | Tricyclic compounds, their production and use | PDGFA, HGF, REN | EPHX1 393/4885NPY5R 1237/4885IDO1 795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.